Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

IDH-mutant glioma

What is next, and who is running it?

The next dated milestone on each program. A hollow marker is a registry primary completion date, not a company readout.

A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.

Include Phase 1
ClassNone selected

11 of 15 programs on this timeline

202520262027202820292030Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Today

alkylating chemotherapy 2

No dated milestone in 2025 to 2030
No dated milestone in 2025 to 2030

ATR inhibitor (ATRX-altered) 1

TuvusertibPhase 2
No dated milestone in 2025 to 2030

mutant IDH1 inhibitor 2

FDA Fast Track granted, Aug 20, 2026
No dated milestone in 2025 to 2030

mutant IDH1/IDH2 inhibitor 2

VorasidenibApproved
No dated milestone in 2025 to 2030
No dated milestone in 2025 to 2030

PARP inhibitor 1

OlaparibPhase 2
No dated milestone in 2025 to 2030

PD-1 antibody 1

NivolumabPhase 2
No dated milestone in 2025 to 2030

peptide vaccine 1

No dated milestone in 2025 to 2030

retinoid plus PD-1 antibody 1

No dated milestone in 2025 to 2030